Andreas K Klein MD

Hematologic Oncology

Wellforce

750 Washington StBoston, MA 02111
Phone+1 617-636-5000
Fax+1 617-636-6204

Dr. Klein is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klein's full profile Already have an account?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Tufts Medical CenterResidency, Internal Medicine, 1995 - 1998
Yale School of MedicineClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2001 - 2027
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
NC State Medical License 1998 - 2001
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014, 2016-2017, 2019-2022
CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2015
Super Doctor SuperDoctors.com

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)
COMPLETED
PHASE3
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
TERMINATED
PHASE1
A Phase II Study of Umbilical Cord Blood Transplantation
TERMINATED
PHASE2

Publications & Presentations

PubMed

Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.
Emily Anderson, Yun Choi, Rachel J Buchsbaum, Andreas Klein, Bonnie Ky
Leukemia & Lymphoma. 2025-08-01
2 citations
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter
Blood Advances. 2024-04-09
12 citations
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
James N Gerson, Elizabeth Handorf, Diego Villa, Alina S Gerrie, Parv Chapani
Blood Advances. 2023-12-26

Journal Articles

Clinicopathologic Characteristics of Secondary Squamous Cell Carcinoma of Head and Neck in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation for Hematolo...
Kenneth B Miller, Kellie A Sprague, Chakra P Chaulagain, Esha Kaul, Andreas K Klein, Janet Cowan, Nature

Abstracts/Posters

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Andreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Andreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia Therapy
Andreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Center for Health Literacy Research + PracticeAugust 23rd, 2024
Development and Clinical Application of CD19xCD3 and CD20xCD3 Bispecific AntibodiesJanuary 17th, 2022
Old Idea, New Desperation: Can Plasma from Recovered Patients Help Those Now Battling COVID-19?May 22nd, 2020